News - Cardio-vascular

Filter

Current filters:

Cardio-vascular

Popular Filters

76 to 100 of 520 results

Actelion’s PAH drugs boost 4% rise in sales

Actelion’s PAH drugs boost 4% rise in sales

17-10-2013

Actelion has announced its financial results for the first nine months of 2013 revealing product sales…

ActelionBiotechnologyCardio-vascularCeptaris TherapeuticsEuropeFinancialTracleerVeletriVentavisZavesca

FDA advisory panel goes negative on Amarin’s Vascepa

FDA advisory panel goes negative on Amarin’s Vascepa

17-10-2013

US biotech firm Amarin revealed yesterday that the US Food and Drug Administration Endocrinologic and…

AmarinBiotechnologyCardio-vascularNorth AmericaRegulationVascepa

Sanofi’s alirocumab monotherapy reduced LDL cholesterol three times more than ezetimibe

Sanofi’s alirocumab monotherapy reduced LDL cholesterol three times more than ezetimibe

16-10-2013

Sanofi and partner Regeneron Pharmaceuticals this morning released results from the Phase III ODYSSEY…

BiotechnologyCardio-vascularPharmaceuticalRegeneronResearchSanofi

FDA approves Bayer’s Adempas; firm accelerates drug candidates

FDA approves Bayer’s Adempas; firm accelerates drug candidates

09-10-2013

The US Food and Drug Administration late yesterday approved Adempas (riociguat), developed by German…

AdempasBayerCardio-vascularcopanlisibfinerenoneNorth AmericaOncologyPharmaceuticalRegulationResearchRespiratory and PulmonaryWomen's Health

Case study draws attention to innovator brand preferences in Kenya

08-10-2013

Some of the stronger performing brands in Kenya’s pharmaceutical market have been highlighted in a…

Antibiotics and Infectious diseasesCardio-vascularDiabetesGlaxoSmithKlineMarkets & MarketingPharmaceuticalRest of the World

Japanese lawmakers are stepping in to Diovan investigation

07-10-2013

Members of Japan’s Diet (Congressmen) have formed a bipartisan study group to examine Swiss drug major…

Asia-PacificCardio-vascularDiovanNovartisPharmaceuticalPoliticsRegulationResearch

Ph I cholesterol lowerer offers new hope for patients resistant to statins

04-10-2013

A study published in The Lancet found that participants in a Phase I clinical trial saw their level of…

ALN-PCSAlnylam PharmaceuticalsBiotechnologyCardio-vascularResearch

Xention and Servier sign up for cardiovascular collaboration

Xention and Servier sign up for cardiovascular collaboration

02-10-2013

Xention and Servier have entered into a multi-year agreement for the development and commercialization…

BiotechnologyCardio-vascularLicensingServierXention

GlaxoSmithKline agrees £700 million deal with Aspen

GlaxoSmithKline agrees £700 million deal with Aspen

30-09-2013

GlaxoSmithKline says it has now reached agreement to sell its thrombosis brands, Arixtra and Fraxiparine,…

ArixtraAspen PharmacareCardio-vascularFraxiparineGlaxoSmithKlineMergers & AcquisitionsPharmaceuticalRest of the World

Novartis under investigation for manipulating data in Japanese clinical trials

Novartis under investigation for manipulating data in Japanese clinical trials

27-09-2013

Swiss drug major Novartis has said it regrets the inconvenience caused by its investigator-initiated…

Asia-PacificCardio-vascularLegalNovartisPharmaceuticalRegulationvalsartan

Sanofi strengthens its presence in Algeria with €70 million investment

Sanofi strengthens its presence in Algeria with €70 million investment

26-09-2013

French drug major Sanofi revealed today that construction has begun on its new Sidi Abdellah industrial…

Cardio-vascularDiabetesFinancialPharmaceuticalProductionRest of the WorldSanofi

Phase III pooled EINSTEIN studies reaffirm Bayer's Xarelto role for venous thromboembolism

Phase III pooled EINSTEIN studies reaffirm Bayer's Xarelto role for venous thromboembolism

22-09-2013

Data from the Phase III EINSTEIN clinical trial program published Friday in the Thrombosis Journal underline…

BayerCardio-vascularPharmaceuticalResearchXarelto

Teva's exclusive launch of generic Niaspan in the USA

22-09-2013

Israel-based Teva Pharmaceutical Industries (NYSE: TEVA), the world biggest maker of generic drugs, on…

AbbVieCardio-vascularMarkets & MarketingNiaspanNorth AmericaTeva Pharmaceutical Industries

Cytomedix reorganizes R&D to cut cash burn

18-09-2013

US biotechnology company Cytomedix (OTCQX: CMXI) will reorganize its R&D activities to reduce cash burn.…

BiotechnologyCardio-vascularCytomedixFinancialNorth America

Cardiome in deal for commercialization of Brinavess in Israel

18-09-2013

Canada-based Cardiome Pharma (TSX: COM) has entered into an agreement with Tzamal Medical to sell and…

BrinavessCardio-vascularCardiome PharmaLicensingPharmaceuticalRest of the WorldTzamal Medical

US FDA accepts Epanova NDA filing

18-09-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) today announced that the US Food and Drug Administration…

AstraZenecaCardio-vascularEpanovaNorth AmericaOmthera PharmaceuticalsPharmaceuticalRegulation

Takeda out-licenses Edarbi and Edarbyclor

13-09-2013

Japan's largest drugmaker Takeda Pharmaceutical (TYO: 4502) has entered into a license, development and…

Arbor PharmaceuticalsCardio-vascularEdarbiEdarbyclorLicensingNorth AmericaPharmaceuticalTakeda Pharmaceuticals

Positive data on RVX-208 pushes Resverlogix shares higher

06-09-2013

Canadian biotech firm Resverlogix (TSX:RVX) saw its shares rocket 40% to C$0.95 after it released a full…

BiotechnologyCardio-vascularResearchResverlogixRVX-208

Ireland's HSE announces preferred ACE inhibitor and ARBs

06-09-2013

Ireland Health Service Executive's (HSE) Medicines Management Program (MMP) has identified two new preferred…

Cardio-vascularEuropeFinancialGenericsPricing

Sanofi US in deal to commercialize PA8140/PA32540

04-09-2013

The US subsidiary of French drug major Sanofi (Euronext: SAN) has entered into a deal with US drugmaker…

AspirinCardio-vascularGastro-intestinalsLicensingNorth AmericaOmeprazolePharmaceuticalPozenSanofi

Boehringer Ingelheim plans to expand body of evidence for Pradaxa

04-09-2013

German family-owned drug major Boehringer Ingelheim has announced new milestones for the novel oral anticoagulant…

Boehringer IngelheimCardio-vascularPharmaceuticalPradaxaResearch

76 to 100 of 520 results

Company Spotlight

Fibrotech

Fibrotech

Back to top